October 6th 2010 | Biologics, Health care system, Public policy issues, psoriatic arthritis | 0 Comments
In what may be a look at the future of the U.S. health care system, the National Institute for Health and Clinical Excellence (NICE) in Britain has recommended denying psoriatic arthritis patients reimbursement for the biologic Simponi (golimumab) in the country’s government-run health care system.
NICE has generated great controversy in the United States, with President
READ THE FULL POST
May 26th 2009 | Biologics, Treatment, psoriatic arthritis | 0 Comments
On April 24, the U.S. Food and Drug Administration (FDA) approved Simponi (golimumab) for the treatment of three forms of arthritis, including active psoriatic arthritis. Described in media reports as a “potential blockbuster drug,” Simponi is administered once monthly via injection under the skin. As WebMD put it: “Simponi is in a
READ THE FULL POST
